BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 22783570)

  • 1. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
    Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W
    Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
    Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
    Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
    Abd-El Raouf SM; Ibrahim TR
    Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules.
    Cui W; Sang W; Zheng S; Ma Y; Liu X; Zhang W
    Clin Lab; 2012; 58(7-8):673-80. PubMed ID: 22997967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
    Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
    Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
    Aron M; Kapila K; Verma K
    Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
    Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
    Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
    Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
    J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
    Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
    Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma.
    Jakubiak-Wielganowicz M; Kubiak R; Sygut J; Pomorski L; Kordek R
    Pol J Pathol; 2003; 54(2):111-5. PubMed ID: 14575419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions.
    Oestreicher-Kedem Y; Halpern M; Roizman P; Hardy B; Sulkes J; Feinmesser R; Stern Y
    Head Neck; 2004 Nov; 26(11):960-6. PubMed ID: 15386597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry.
    Feilchenfeldt J; Tötsch M; Sheu SY; Robert J; Spiliopoulos A; Frilling A; Schmid KW; Meier CA
    Mod Pathol; 2003 Nov; 16(11):1117-23. PubMed ID: 14614051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications.
    Xu XC; el-Naggar AK; Lotan R
    Am J Pathol; 1995 Sep; 147(3):815-22. PubMed ID: 7677193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
    de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
    Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation.
    Atik E; Guray M; Gunesacar R; Ozgur T; Canda T
    Indian J Cancer; 2014; 51(1):63-8. PubMed ID: 24947099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Ki-67 as a proliferative marker in lesions of thyroid.
    Pujani M; Arora B; Pujani M; Singh SK; Tejwani N
    Indian J Cancer; 2010; 47(3):304-7. PubMed ID: 20587907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue.
    Fernández PL; Merino MJ; Gómez M; Campo E; Medina T; Castronovo V; Sanjuán X; Cardesa A; Liu FT; Sobel ME
    J Pathol; 1997 Jan; 181(1):80-6. PubMed ID: 9072007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer.
    Weber KB; Shroyer KR; Heinz DE; Nawaz S; Said MS; Haugen BR
    Am J Clin Pathol; 2004 Oct; 122(4):524-31. PubMed ID: 15487449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors.
    Wang O; Wang CY; Shi J; Nie M; Xia WB; Li M; Jiang Y; Guan H; Meng XW; Xing XP
    Chin Med J (Engl); 2012 Aug; 125(16):2895-901. PubMed ID: 22932087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
    Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T
    Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.